<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (MS), <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and abnormal fibrinolytic function are frequently present, mostly owing to an increase in plasminogen activator inhibitor-1(PAI-1) </plain></SENT>
<SENT sid="1" pm="."><plain>We analyze PAI-1 in pregnant women, both <z:mpath ids='MPATH_458'>normal</z:mpath> and with <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>) and postpartum regarding its correlation to MS surrogates </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical characteristics, <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (100g-OGTT), <z:chebi fb="23" ids="18059">lipids</z:chebi>, PAI-1 antigen, insulin sensitivity (HOMA-S), and pancreatic beta-cell function (HOMA-B) were investigated in 34 women </plain></SENT>
<SENT sid="3" pm="."><plain>Eleven had <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT) during pregnancy and 23 had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> (<z:hpo ids='HP_0000001'>all</z:hpo> GAD antibodies-negative) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were studied at 28-34 weeks of gestation and 16-24 weeks after delivery (75 g-OGTT) </plain></SENT>
<SENT sid="5" pm="."><plain>Parameters of interest were determined using commercial test systems </plain></SENT>
<SENT sid="6" pm="."><plain>During pregnancy, PAI-1 was not statistically different between NGT and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> (47+/-25 ng/ml versus 47+/-28 ng/ml, p=0.9) </plain></SENT>
<SENT sid="7" pm="."><plain>After gestation, 19 (56%) women had NGT (11 of them from previous NGT group) and 15 (44%) had <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) or DM </plain></SENT>
<SENT sid="8" pm="."><plain>The IGT (IGT+DM) group had higher PAI-1 (p=0.01), which did not decreased after delivery NGT-NGT before and after delivery (47+/-25 ng/ml versus 6+/-5 ng/ml; p&lt;0.001), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>-NGT (62+/-36 ng/ml versus 14+/-15 ng/ml; p=0.001) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>-IGT (39+/-20 ng/ml versus 27+/-23 ng/ml; p=0.15) </plain></SENT>
<SENT sid="9" pm="."><plain>PAI-1 levels were positively correlated (p&lt;0.05) to total cholesterol (r(s)=0.37), <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (r(s)=0.48), fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (r(s)=0.52), 2-h plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> in the OGTT (r(s)=0.58) and were negatively correlated (p&lt;0.05) with HOMA-S (r(s)=-0.42) and HOMA-B (r(s)=-0.38) </plain></SENT>
<SENT sid="10" pm="."><plain>Fibrinolytic dysfunction is still present in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> women and is associated with early development of IGT or T2DM </plain></SENT>
<SENT sid="11" pm="."><plain>PAI correlated with surrogate markers of MS levels and may identify a group of women at risk for <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e> </plain></SENT>
</text></document>